Bio-Images Research appoints director of regulatory affairs

To maintain highest level of ethical standards as firm expands

Clinical research firm Bio-Images Research has appointed a director of regulatory affairs.

Dr Sarah Connolly, who has been with the Glasgow-based company for the past four years, will take responsibility for GMP, regulatory and ethical approvals.

The appointment is designed to maintain the highest level of ethical and regulatory standards as the company's pipeline of clinical studies steadily increases.

Bio-Images has completed three clinical studies this year and claims to be in the forefront of a small field of providers of gamma scintigraphy imaging services, which allow multi-national pharma companies to outsource some of their clinical research.

Dr Connolly joined the company after completing her PhD in Pharmaceutical Sciences at the University of Strathclyde in 2007.

You may also like

Regulatory

Bio-Images Group and CPS Research form partnership

Glasgow firms will combine formulation development and clinical trial capabilities
Regulatory

Grifols receives US FDA approval for new fibrinogen concentrate: FESILTY (fibrinogen, human-chmt)

The fibrinogen concentrate complements Grifols’ bleeding management portfolio, expanding therapeutic options for patients
Regulatory

Hansa Biopharma submits BLA to FDA for Imlifidase in desensitisation for kidney transplantation

Imlifidase is an enzyme that rapidly and efficiently cleaves all types of immunoglobulin G (IgG) antibodies both intra- and extra-vascularly to inhibit IgG-mediated immune response
Research & Development

CHITOSE and FUJIFILM Biosciences form strategic alliance to drive global innovation and biopharmaceutical manufacturing

Collaboration formed to accelerate biopharmaceutical manufacturing, combining high-performing CHO-MK cells and GMP-manufactured culture media
Regulatory

New pharmaceutical legislation in Europe agreed

The agreement is the most significant overhaul of the regulatory framework in more than 20 years and represents a huge opportunity to reshape medicines regulation in the EU
Manufacturing

Why aseptic processing is critical for microsphere drug manufacturing

As microsphere-based drug delivery systems move from niche innovation to commercial reality, manufacturers face growing pressure to guarantee sterility without compromising product integrity. Aseptic processing has become essential to meeting both regulatory expectations and patient safety requirements
Research & Development

Groundbreaking research suggests plastic waste could be used to make anti-cancer drugs

A discovery made by the University of St Andrews has revealed a way to turn ordinary household plastic waste into the building block for anti-cancer treatments
Subscribe now